Everolimus causing severe hypertriglyceridemia and acute pancreatitis

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 1, 2013, Pages 5-9

  Subramaniam, Somasundaram ^a   Zell, Jason A ^b   Kunz, Pamela L ^a  

^a STANFORD CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CHROMOGRANIN A; EVEROLIMUS; FENOFIBRATE; OMEPRAZOLE; OXALIPLATIN; PANCREAS POLYPEPTIDE; TEMOZOLOMIDE; ZOLEDRONIC ACID;

ABDOMINAL DISCOMFORT; ACUTE PANCREATITIS; ADULT; APHERESIS; ARTICLE; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CASE REPORT; DEFECATION HABIT; DIARRHEA; DRUG WITHDRAWAL; FATIGUE; GASTRIN BLOOD LEVEL; GLUCAGON BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROPATHY; PANCREATIC NEUROENDOCRINE TUMOR; PERCUTANEOUS VERTEBROPLASTY; RASH; SEROTONIN BLOOD LEVEL; SPINAL CORD METASTASIS; STOMATITIS; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR BIOPSY; TUMOR BLEEDING; VOMITING;

EID: 84874629080     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0003     Document Type: Article

References (18)

1. Common Terminology Criteria for Adverse Events v4.0. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11. pdf. Accessed July 5, 2012.
2. Afinitor prescribing information. Available at: http://www.pharma.us. novartis.com/product/pi/pdf/afinitor.pdf. Accessed July 5, 2012.
3. Common Terminology Criteria for Adverse Events v3.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf. Accessed July 5, 2012.
4. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372;449-456.
5. Yao JC, Shah MH, Ito T, et al. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) study group. N Engl J Med 2011;364:514-523.
6. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 2012;366:520-529.
7. Bissler JJ, Kingswood C, Zonnenberg BA, et al. Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: results from EXIST-2 [abstract]. J Clin Oncol 2012;30(Suppl 5):Abstract 356.
8. Harzstark AL, Small EJ, Weinberg VK, et al. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 2011;117:4194-4200.
9. Kasike BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients Am J Transpl 2008;8:1384-1392.
10. Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006;12:1640-1648.
11. Erratum in: Liver Transpl 2006;12:1726.
12. Kovarik JM, Snell GI, Valentine V, et al. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. J Heart Lung Transplant 2006;25:440-446.
13. Toskes AU. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am 1990;19:783.
14. Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol 2003;36:54-62.
15. Gan SI, Edwards AL, Symonds AL, et al. Hypertriglyceridemia-induced pancreatitis: a case-based review. World J Gastroenterol 2006;12:7197-7202.
16. Yeh J, Chen J, Chiu H. Plasmapheresis for hyperlipidemic pancreatitis. J Clin Apheresis 2003;18:181-185.
17. Tsuang W, Navaneethan U, Ruiz L, et al. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol 2009;104:984-991.
18. Bravo MT, Justo LM, Lasala JP, et al. Acute pancreatitis secondary to neuroendocrine pancreatic tumors: report of 3 cases and literature review. Pancreas 2012;41:485-489.